Zhejiang Jingxin Pharmaceutical Co., Ltd.

Symbol: 002020.SZ

SHZ

12.13

CNY

Market price today

  • 16.3059

    P/E Ratio

  • 0.3339

    PEG Ratio

  • 10.44B

    MRK Cap

  • 0.02%

    DIV Yield

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020-SZ) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.50%

Operating Profit Margin

0.16%

Net Profit Margin

0.16%

Return on Assets

0.08%

Return on Equity

0.12%

Return on Capital Employed

0.11%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Jin Zhiping
Full-time employees:3909
City:Xinchang
Address:No. 800, East Road
IPO:2004-07-15
CIK:

Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products in China. The company offers APIs, antihypertensive products, antibiotics, quinolones, gastrointestinal promotions, antidiabetics, antipileptics, antihistamines, H+ pump depressants, antihyper cholesterolemia products, histamine H2 receptor blokades, antihyper cholesterolemirs, antidepressants, cephalosporin products, and biopharma products. It also provides diagnostic medical displays, surgical medical displays, clinical medical displays, medical large screens, medical integrated machines, ultrasonic medical displays, and other products. The company was formerly known as Zhejiang Jingxin Pharmaceutical Factory and changed its name to Zhejiang Jingxin Pharmaceutical Co., Ltd. in 2000. Zhejiang Jingxin Pharmaceutical Co., Ltd. was founded in 1974 and is headquartered in Xinchang, China.

General Outlook

When we look at how much money they make before expenses, they keep 0.504% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.161%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.157%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.077% return, is a testament to Zhejiang Jingxin Pharmaceutical Co., Ltd.'s adeptness in optimizing resource deployment. Zhejiang Jingxin Pharmaceutical Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.117%. Furthermore, the proficiency of Zhejiang Jingxin Pharmaceutical Co., Ltd. in capital utilization is underscored by a remarkable 0.108% return on capital employed.

Stock Prices

Zhejiang Jingxin Pharmaceutical Co., Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $10.95, while its low point bottomed out at $10.64. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Zhejiang Jingxin Pharmaceutical Co., Ltd.'s stock market.

Liquidity Ratios

Analyzing 002020.SZ liquidity ratios reveals its financial health of the firm. The current ratio of 163.07% gauges short-term asset coverage for liabilities. The quick ratio (124.80%) assesses immediate liquidity, while the cash ratio (92.12%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio163.07%
Quick Ratio124.80%
Cash Ratio92.12%

Profitability Ratios

002020.SZ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 18.01% underscores its earnings before tax deductions. The effective tax rate stands at 12.29%, revealing its tax efficiency. The net income per EBT, 86.89%, and the EBT per EBIT, 111.74%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 16.12%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin18.01%
Effective Tax Rate12.29%
Net Income per EBT86.89%
EBT per EBIT111.74%
EBIT per Revenue16.12%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.63, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 654.21% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding125
Days of Inventory Outstanding117
Operating Cycle172.84
Days of Payables Outstanding188
Cash Conversion Cycle-15
Receivables Turnover6.54
Payables Turnover1.95
Inventory Turnover3.12
Fixed Asset Turnover1.72
Asset Turnover0.49

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 1.12, and free cash flow per share, 0.72, depict cash generation on a per-share basis. The cash per share value, 2.55, showcases liquidity position. A payout ratio of 0.40 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.23, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share1.12
Free Cash Flow per Share0.72
Cash per Share2.55
Payout Ratio0.40
Operating Cash Flow Sales Ratio0.23
Free Cash Flow to Operating Cash Flow Ratio0.64
Cash Flow Coverage Ratio2.55
Short Term Coverage Ratio2.78
Capital Expenditure Coverage Ratio2.81
Dividend Paid and Capex Coverage Ratio1.60
Dividend Payout Ratio0.02

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 4.49%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.07, we discern the balance between debt and equity financing. The long-term debt to capitalization, 0.54%, and total debt to capitalization, 6.17%, ratios shed light on its capital structure. An interest coverage of 100.24 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio4.49%
Debt Equity Ratio0.07
Long Term Debt to Capitalization0.54%
Total Debt to Capitalization6.17%
Interest Coverage100.24
Cash Flow to Debt Ratio2.55
Company Equity Multiplier1.47

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 4.59, provides a glimpse into top-line earnings distributed across each share. Net income per share, 0.72, reflects the portion of profit attributed to each share. The book value per share, 6.40, represents the net asset value distributed per share, while the tangible book value per share, 5.88, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share4.59
Net Income Per Share0.72
Book Value Per Share6.40
Tangible Book Value Per Share5.88
Shareholders Equity Per Share6.40
Interest Debt Per Share0.77
Capex Per Share-0.60

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 4.56%, indicates top-line expansion, while the gross profit growth, -5.46%, reveals profitability trends. EBIT growth, -23.45%, and operating income growth, -23.45%, offer insights into operational profitability progression. The net income growth, -6.55%, showcases bottom-line expansion, and the EPS growth, -6.49%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth4.56%
Gross Profit Growth-5.46%
EBIT Growth-23.45%
Operating Income Growth-23.45%
Net Income Growth-6.55%
EPS Growth-6.49%
EPS Diluted Growth-6.49%
Weighted Average Shares Growth0.11%
Weighted Average Shares Diluted Growth0.11%
Dividends per Share Growth-0.21%
Operating Cash Flow Growth-3.63%
Free Cash Flow Growth-10.30%
10-Year Revenue Growth per Share185.14%
5-Year Revenue Growth per Share35.21%
3-Year Revenue Growth per Share11.46%
10-Year Operating CF Growth per Share422.19%
5-Year Operating CF Growth per Share58.69%
3-Year Operating CF Growth per Share47.66%
10-Year Net Income Growth per Share576.19%
5-Year Net Income Growth per Share68.45%
3-Year Net Income Growth per Share-12.92%
10-Year Shareholders Equity Growth per Share373.79%
5-Year Shareholders Equity Growth per Share55.87%
3-Year Shareholders Equity Growth per Share29.29%
10-Year Dividend per Share Growth per Share467.61%
5-Year Dividend per Share Growth per Share82.17%
3-Year Dividend per Share Growth per Share0.82%
Receivables Growth16.49%
Inventory Growth-15.64%
Asset Growth8.48%
Book Value per Share Growth7.00%
Debt Growth120.21%
R&D Expense Growth1.29%
SGA Expenses Growth12.62%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 10,194,136,415.8, captures the company's total value, considering both debt and equity. Income quality, 1.33, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.02, gauges operational efficiency, while the research and development to revenue, 9.41%, highlights investment in innovation. The ratio of intangibles to total assets, 9.39%, indicates the value of non-physical assets, and capex to operating cash flow, -63.00%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value10,194,136,415.8
Income Quality1.33
Sales General and Administrative to Revenue0.02
Research and Development to Revenue9.41%
Intangibles to Total Assets9.39%
Capex to Operating Cash Flow-63.00%
Capex to Revenue-13.15%
Capex to Depreciation-234.58%
Graham Number10.18
Return on Tangible Assets8.55%
Graham Net Net0.77
Working Capital1,278,975,985
Tangible Asset Value5,059,219,224
Net Current Asset Value1,176,145,705
Average Receivables617,021,178
Average Payables664,986,397
Average Inventory713,193,455.5
Days Sales Outstanding61
Days Payables Outstanding109
Days of Inventory On Hand116
ROIC8.28%
ROE0.11%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.83, and the price to book ratio, 1.83, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.57, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 17.04, and price to operating cash flows, 10.91, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.83
Price to Book Ratio1.83
Price to Sales Ratio2.57
Price Cash Flow Ratio10.91
Price Earnings to Growth Ratio0.33
Enterprise Value Multiple16.44
Price Fair Value1.83
Price to Operating Cash Flow Ratio10.91
Price to Free Cash Flows Ratio17.04
Price to Tangible Book Ratio1.99
Enterprise Value to Sales2.58
Enterprise Value Over EBITDA12.73
EV to Operating Cash Flow12.36
Earnings Yield5.65%
Free Cash Flow Yield2.79%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) on the SHZ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 16.306 in 2024.

What is the ticker symbol of Zhejiang Jingxin Pharmaceutical Co., Ltd. stock?

The ticker symbol of Zhejiang Jingxin Pharmaceutical Co., Ltd. stock is 002020.SZ.

What is company IPO date?

IPO date of Zhejiang Jingxin Pharmaceutical Co., Ltd. is 2004-07-15.

What is company current share price?

Current share price is 12.130 CNY.

What is stock market cap today?

The market cap of stock today is 10444281770.000.

What is PEG ratio in 2024?

The current 0.334 is 0.334 in 2024.

What is the number of employees in 2024?

In 2024 the company has 3909.